<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05792644</url>
  </required_header>
  <id_info>
    <org_study_id>XLi</org_study_id>
    <nct_id>NCT05792644</nct_id>
  </id_info>
  <brief_title>Therapeutic Effect of Crizotinib for Rearrangement-negative, High Phosphorylated ALK Patients</brief_title>
  <official_title>The Therapeutic Effect of Crizotinib in Patients With ALK-rearrangement-negative But High Expression of ALK Phosphorylation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with histologically or cytologically confirmed stage IIIB or IV ALK-negative&#xD;
      non-small-cell lung cancer (NSCLC) participated in this study following the failure of&#xD;
      initial treatments. The ALK phosphorylation expression was detected in histologic samples of&#xD;
      patients. patients with positive ALK phosphorylation expression were treated with crizotinib&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some patients with histologically or cytologically confirmed stage IIIB or IV ALK-negative&#xD;
      non-small-cell lung cancer (NSCLC) participated in this study following the failure of&#xD;
      initial treatments. The ALK phosphorylation expression was detected in histologic samples of&#xD;
      patients. patients with positive ALK phosphorylation expression were treated with crizotinib&#xD;
      250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">March 1, 2023</completion_date>
  <primary_completion_date type="Actual">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Some patients with histologically or cytologically confirmed stage IIIB or IV ALK-negative non-small-cell lung cancer (NSCLC) participated in this study following the failure of initial treatments. The ALK phosphorylation expression was detected in histologic samples of patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>SIx months</time_frame>
    <description>The clinical efficacy was evaluated according to the RECIST 1.1 guidelines[5], including PD, stable disease (SD), partial response (PR), and complete remission (CR), where the objective response rate (ORR) = (CR + PR) number of cases/total number of cases, and the disease control rate (DCR) = (CR + PR + SD) number/total number of cases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>The progression-free survival (PFS) was defined as the time from the date of first treatment to any recurrence or last follow-up.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>ALK Phosphorylation</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib for rearrangement-negative, high phosphorylated ALK patients</intervention_name>
    <description>Patients with positive ALK phosphorylation expression were treated with crizotinib 250 mg/day orally. A treatment cycle was defined as 30 days of once-daily crizotinib treatment. Treatment with crizotinib continued until the patient experienced unacceptable toxicity, was pregnant, or started new cancer therapy.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 years and 80 years&#xD;
&#xD;
          2. Histologically or cytologically confirmed stage IIIB or IV ALK-negative NSCLC by NGS&#xD;
&#xD;
          3. Disease staging determined according to the International Association for the Study of&#xD;
             Lung Cancer 8th edition TNM staging system&#xD;
&#xD;
          4. All measurable Response Evaluation Criteria in Solid Tumors (RECIST) target lesions&#xD;
&#xD;
          5. Treatment failure at the end of the most recent treatment episode&#xD;
&#xD;
          6. World Health Organization/Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             0-2&#xD;
&#xD;
          7. Consent of patients for participation in this study&#xD;
&#xD;
          8. Complete clinical data&#xD;
&#xD;
          9. High ALK phosphorylation level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with cognitive impairment, severe psychiatric diseases, or other disorders&#xD;
             likely to impact informed consent&#xD;
&#xD;
          2. Patients with uncontrolled systemic disease&#xD;
&#xD;
          3. Patients with other malignant tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>September 18, 2022</study_first_submitted>
  <study_first_submitted_qc>March 19, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 19, 2023</last_update_submitted>
  <last_update_submitted_qc>March 19, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Xuemeng Li</investigator_full_name>
    <investigator_title>Clinical Doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

